What Is the HVA:VMA Ratio? Normal vs Optimal Range Explained

The HVA:VMA ratio provides information that neither HVA nor VMA can deliver alone—it reveals whether your catecholamine system is balanced or skewed toward one branch. Dopamine and norepinephrine share the same synthetic pathway: tyrosine becomes L-DOPA, then dopamine, then norepinephrine. The conversion of dopamine to norepinephrine is controlled by dopamine-beta-hydroxylase (DBH), an enzyme that requires vitamin C and copper as cofactors. The CTD maps over 280 compounds that interact with DBH and the broader catecholamine synthesis pathway. When the ratio sits between 1.0 and 3.0, it indicates that dopamine production and its conversion to norepinephrine are proceeding at physiologically appropriate rates, with neither branch dominating. The ideal ratio of approximately 2.0 reflects a nervous system that can produce adequate motivation and focus (dopamine) while maintaining appropriate stress responsiveness (norepinephrine).

A low HVA:VMA ratio—below 1.0—signals that dopamine is being rapidly converted to norepinephrine, depleting the dopamine pool. This pattern is characteristic of chronic stress, where the sympathetic nervous system demands continuous norepinephrine output to maintain the fight-or-flight response. PubMed indexes over 3,400 publications on catecholamine metabolite ratios, with clinical analyses linking norepinephrine-dominant profiles to anxiety disorders, post-traumatic stress, chronic pain syndromes, and burnout. The practical implication of a low ratio is that motivational and reward symptoms (apathy, anhedonia, ADHD-like difficulties) coexist with stress-driven symptoms (anxiety, hypervigilance, insomnia), because both reflect the same underlying imbalance—dopamine is being consumed to feed the norepinephrine branch faster than it can be replenished.

A high HVA:VMA ratio—above 4.0—means dopamine is accumulating without adequate conversion to norepinephrine, pointing to impaired DBH enzyme activity. FAERS data document catecholamine imbalances across over 70 medication entries affecting sympathetic nervous system function. The most common correctable causes of low DBH activity are vitamin C deficiency (ascorbate is a stoichiometric cofactor consumed in every DBH reaction) and copper deficiency (copper sits in DBH's active site). Genetic variants in the DBH gene can also reduce enzyme expression, creating a constitutional tendency toward high HVA:VMA ratios. Clinically, these individuals may experience low blood pressure, orthostatic intolerance, and reduced stress resilience—all consequences of inadequate norepinephrine availability despite normal or elevated dopamine. Checking vitamin C, ceruloplasmin (copper status), and serum copper alongside the ratio identifies treatable cofactor deficiencies.